The list of the first batch of A-share "entering the motorcycle" announced that 18 medical and health enterprises including Hengrui pharmaceutical are listed

Source: in the early morning of May 15, 2018, MSCI announced its semi-annual index adjustment results and officially admitted China's a shares into the MSCI Emerging Market Index, which is known in the industry as "entering the market" 234 A shares were included in the MSCI index system with an inclusion factor of 2.5% The A shares will account for 1.26% and 0.39% of the MSCI China Index and MSCI Emerging market index respectively MSci (Morgan Stanley Capital International) is a famous index preparation company in the United States It is a financial supplier integrating equity, fixed assets, hedge funds and stock market index business It has compiled a variety of indexes The MSCI index is the most widely used benchmark index for portfolio managers around the world According to statistics, 97 of the top 100 asset managers in the world are MSCI customers The research department of CICC pointed out that the adjustment is crucial to the Chinese market, perhaps even the most important one in many years MSCI will implement the A-share plan in two steps according to the schedule of "entering into the motorcycle" In June, MSCI will include 232 A shares in China, with an initial inclusion factor of 2.5%; in September, the inclusion factor will increase to 5% CICC expects to attract about $21 billion into the A-share market According to MSCI's stock selection criteria, liquidity is the main consideration for selecting individual stocks According to the data, MSCI's stock selection criteria are as follows: 1 For the listed companies in this country, the market value of the company's shares that can be freely traded by international investors can be determined 2 Adopt the global industry classification standard jointly developed by standard & Poor's and MSCI to classify the listed companies 3.MSCI adopts the bottom-up method to construct the index, that is, at the industry level, the free circulation stocks with large market value are added in turn, so that the free circulation market value of the selected stocks of each industry reaches 85% of that of the industry 4 Fine tune the selected stocks in various industries to make the free circulation market value of the selected stocks reach more than 85% of the whole market The successful inclusion of a shares in MSCI index is conducive to boosting investor sentiment in the short term; in the long term, the participation of overseas investors in a shares will be further improved, and the proportion of professional institutional investors will be further increased Li Daxiao, chief economist of Yingda securities, said that the pace of China's opening up to the outside world is all-round The "A-share" means that China's securities market is internationally recognized, which is a great progress In fact, in recent years, the pace of China's financial opening has never stopped Shanghai Hong Kong stock connect, Shenzhen Hong Kong stock connect and bond stock connect have been opened and implemented successively, and QFII (qualified overseas institutional investor) and rqfii (qualified overseas institutional investor in RMB) have been continuously expanded On April 11, Yi Gang, President of the people's Bank of China, put forward specific measures and timetable for opening up the financial industry to the outside world at the Boao Forum for Asia 2018 annual meeting, including striving to open the "Shanghai Luntong" within 2018, canceling the restrictions on the proportion of foreign shares held by banks and financial asset management companies, etc "In terms of financial markets, we have been working on how to allow foreign investment to enter the stock market and bond market, and how to include China's stock index in the world's major indexes," said Yi Gang It is worth mentioning that from May 1, the daily quota of interconnection has been quadrupled: the daily quota of Shanghai Stock connect and Shenzhen Stock connect has been adjusted from 13 billion yuan to 52 billion yuan, and the daily quota of Hong Kong stock connect has been adjusted from 10.5 billion yuan to 42 billion yuan It is reported that it took six to nine years for South Korea and Taiwan to enter the country in an all-round way Li Daxiao pointed out that there are many factors influencing the inclusion of A-share in MSCI, including its internationalization, openness and liquidity, which basically match the pace of opening up "The pace of China's financial opening is accelerating, which makes it only faster for a shares to be fully incorporated into MSCI than other emerging markets." Which medical and health enterprises are included in the list of a shares of MSCI index this time? Big health sector accounts for 18 The health industry has sorted out the medical and health enterprises that are finally determined to be included in the MSCI index: Tongrentang, Baiyunshan, dong'ejiao, Hengrui pharmaceutical, Jiuzhoutong, Kangmei pharmaceutical, meinian health, East China pharmaceutical, step pharmaceutical, Fosun Pharmaceutical, Tishi, Tonghua Dongbao, Yunnan Baiyao, Pianzihuang, Shanghai pharmaceutical, xinlitai, Kelun pharmaceutical and China Resources 39 Here is a brief introduction of 17 companies, with market value calculated according to the closing price on May 14, 2018 Tongrentang: Tongrentang is a time-honored brand in Chinese medicine industry In June 1997, Beijing Tongrentang Co., Ltd was solemnly listed on the Shanghai Stock Exchange At present, the total market value is 52006 million yuan Baiyunshan: Baiyunshan Pharmaceutical was listed on Shenzhen Stock Exchange in 1993 It is one of the earliest listed companies in China At present, the total market value is 64.365 billion yuan Dong'a-jiao: dong'a-jiao was formerly Shandong dong'a-jiao factory, which was established in 1952 and transformed from a state-owned enterprise into a joint-stock enterprise in 1993 In 1996, it became a listed company On July 29 of the same year, the "dong'a-jiao" A-share stock was listed on the Shenzhen Stock Exchange It is the largest manufacturer of donkey hide gelatin and a series of products in China At present, the total market value is 36.069 billion yuan Hengrui medicine: founded in 1997, Hengrui medicine is a state-owned holding company It officially landed on the main board of Shanghai in 2000 Its products cover many fields, such as anti-tumor drugs, surgical anesthesia drugs, characteristic infusion, contrast agents, cardiovascular drugs, etc., and have formed a relatively complete product layout Industry insiders say Hengrui pharmaceutical is worthy of the title of "A-share pharmaceutical king" According to new wealth statistics, since its listing in October 2000, the stock price of Hengrui pharmaceutical has increased by more than 90 times, with an average annual growth rate of more than 30%, especially in the recent two years, with an average annual growth rate of 70% At present, the total market value is 258.168 billion yuan Jiuzhoutong: a joint-stock enterprise with western medicine, traditional Chinese medicine and medical equipment wholesale, logistics distribution, retail chain and e-commerce as its core business In 2009, the company's tax inclusive sales statistical index was 22 billion yuan, which was the largest private enterprise in Hubei Province It ranked the third among nearly 10000 pharmaceutical commercial enterprises in China and the first among China's private pharmaceutical commercial enterprises It was shortlisted as "top 500 Chinese enterprises" for six consecutive years On November 2, 2010, Jiuzhoutong was listed on the Shanghai Stock Exchange At present, the total market value is 33.967 billion yuan Kangmei pharmaceutical: it is a large-scale pharmaceutical listed company integrating the supply and marketing of drugs, Chinese herbal pieces, health care products and other products Its main source of income is the trade of Chinese herbal medicines Among them, the business of Chinese herbal pieces is oriented to hospitals It has established long-term cooperative relations with more than 2000 medical institutions As the industry leader with the support of the whole industry chain of traditional Chinese medicine, Kangmei pharmaceutical makes money from every link of the trade of traditional Chinese medicine, Chinese herbal pieces, extended commerce and big healthy consumer goods of traditional Chinese medicine, and each link has a "strong moat" Kangmei pharmaceutical was listed on the Shanghai Stock Exchange on March 19, 2001 At present, the total market value is 121.571 billion yuan Meinian health: founded in 2004, with more than 100 physical examination centers nationwide, it is a chain operation organization integrating physical examination, health management and health consultation Meinian health completed backdoor listing in August 2015, and the name of the backdoor company is Jiangsu Sanyou Group Co., Ltd At present, the total market value is 74.241 billion yuan Huadong pharmaceutical: established in 1993, mainly engaged in the production and sales of antibiotics, Chinese patent medicine, chemical synthetic medicine, genetic engineering drugs, and the wholesale and retail distribution business of Chinese and Western medicine, Chinese herbal medicine, medical devices, etc., is a large-scale comprehensive pharmaceutical listed company integrating pharmaceutical research and development, pharmaceutical industry, drug distribution, retail sales, and pharmaceutical logistics, undertaking the national, provincial and municipal administration Special storage of government drugs The company was listed on Shenzhen Stock Exchange in December 1999 At present, the total market value is 69.701 billion yuan Step pharmaceutical: a national traditional Chinese medicine enterprise started in Xianyang, Shaanxi Province Naoxintong capsule, Wenxin Granules, Danhong injection, etc are common medicines for cardiovascular and cerebrovascular patients in China In 2016, they landed in the main board market of Shanghai Stock Exchange and set the highest issuing price record since that year - 55.88 yuan / share At present, the total market value is 33.95 billion Fosun Pharmaceutical: founded in 1994 and listed on the Shanghai Stock Exchange in August 1998, it is a leading listed company in China's pharmaceutical industry At present, the total market value is 105.095 billion yuan Tianshili: it is a high-tech enterprise group with big health industry as the main line and pharmaceutical industry as the center, including modern Chinese medicine, chemical medicine, biopharmaceutical and health products, health food, etc., covering scientific research, planting, extraction, preparation, marketing, etc it is one of the key large enterprise groups supported by Tianjin The company was listed on the Shanghai Stock Exchange on August 23, 2002 At present, the total market value is 45.834 billion yuan Tonghua Dongbao: in 1984, Li Yikui, a private entrepreneur, founded Baishan tonic factory in Tonghua City, Jilin Province In 1992, it began to carry out share-holding restructuring In 1994, it was officially listed on the A-share market Its products are insulin and capsule for injection, which are mainly sold to countries around the world At present, the total market value is 48.772 billion yuan Yunnan Baiyao: in August 1984, the former State Administration of traditional Chinese medicine listed Yunnan Baiyao formula and technology as the top secret of the state On November 30, 1993, Yunnan Baiyao first landed in the capital market At present, the total market value is 110.742 billion yuan Pianzehuang: it is a national high-tech enterprise and a time-honored brand enterprise of China It was founded in 1956 by the former Zhangzhou pharmaceutical factory, and was restructured and established in December 1999 In June 2003, pianzehuang pharmaceutical stock was successfully listed on the Shanghai Stock Exchange At present, the total market value is 61.46 billion yuan Shanghai Pharmaceutical: established by Shanghai Pharmaceutical (Group) Co., Ltd by replacing all the assets of Shanghai four Pharmaceutical Co., Ltd with the high-quality assets of its former wholly-owned subsidiaries Shanghai Pharmaceutical Co., Ltd., Shanghai Pharmaceutical Industry Sales Co., Ltd and Shanghai Tianping pharmaceutical factory It was re listed on September 9, 1998 Its main businesses are pharmaceutical manufacturing, pharmaceutical distribution and pharmaceutical retail At present, the total market value is 71.876 billion yuan Xinlitai: established in 1998, it is a comprehensive pharmaceutical group integrating research and development, production and sales of pharmaceutical products It is mainly engaged in research and development, production and sales of cardiovascular, cephalosporin antibiotics, bone absorption inhibitors and other drugs It was listed in Shenzhen Stock Exchange in 2009 At present, the total market value is 42.74 billion yuan Kelun pharmaceutical: founded in 1996, is the largest professional infusion manufacturer in China On June 3, 2010, Kelun pharmaceutical was listed in the small and medium-sized plates of Shenzhen Stock Exchange At present, the total market value is 49.421 billion yuan China Resources 39: a large state-owned listed pharmaceutical company, formerly known as Shenzhen Nanfang pharmaceutical factory On April 21, 1999, the establishment of a joint stock company was initiated It was listed on Shenzhen Stock Exchange on March 9, 2000 and officially entered China Resources Group at the end of November 2007 Mainly engaged in research and development, production, sales and related health services of pharmaceutical products At present, the total market value is 27.48 billion yuan.